Opinion|Videos|December 24, 2024
Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses additional noteworthy data from CHEST 2024 on emerging therapies for IPF and PAH and highlights his excitement for ongoing research focused on improving early detection, personalized treatments, and improving long-term patient outcomes.
Advertisement
Episodes in this series
- Please discuss any other data in IPF or PAH released at CHEST 2024 that you find noteworthy to share with colleagues.
- Outside of CHEST 2024, what ongoing research efforts are you most excited about in the treatment and management of IPF and PAH, and what are some key areas where you think further research is needed to continue improving patient outcomes?
Advertisement
Related to this article
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.
Older patients with obstructive sleep apnea (OSA) had more cardiometabolic disease and poorer reported sleep quality than younger patients.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
5 Things to Know About the One Big Beautiful Bill Act
3
New CHEST Guidelines Offer a Road Map for Bronchiectasis
4
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
5